About Alnylam

Our Science Is Changing the Way Medicine Treats DiseaseTM

Alnylam has led the translation of RNAi (RNA interference) from Nobel Prize-winning discovery into an innovative, entirely new class of medicines. Founded in 2002 by a team of distinguished life sciences leaders, Alnylam’s vision is to harness the potential of RNAi therapeutics to transform the lives of people living with diseases for which there are limited or inadequate treatment options. Our pioneering work has delivered the world’s first and only approved RNAi therapeutics—ONPATTRO® (patisiran) in 2018, GIVLAARI® (givosiran) in 2019, and OXLUMO® (lumasiran) in 2020. We are advancing a deep pipeline of innovative RNAi-based medicines in four therapeutic areas: genetic medicines, cardio-metabolic diseases, infectious diseases, and central nervous system (CNS) and ocular diseases.

What’s in a Name?

AL-NY-LAM. Our name may not be the easiest to pronounce, but once you learn it, you’ll never forget it. Alnylam is derived from “Alnilam,” the bright center star in the constellation Orion’s belt, which has been used by navigators for thousands of years and symbolizes our passion for discovery.

RNAi Therapeutics—An Innovative New Class of Medicines

Medicines based on RNAi work by “silencing” or disabling the production (“expression”) of the genes that cause specific diseases. In doing so, RNAi therapeutics work “upstream” of most other classes of medicines, such as small molecules and monoclonal antibodies, by targeting the “root” genetic cause of a disease rather than its symptoms. To learn more about our science, click here.


RNAi is the core discovery that forms the therapies Alnylam is developing. It is recognized as a major scientific breakthrough—but how does it work, exactly?

Learn About How RNAi-Based Medicines Work

Vision, Mission, and Values

Our Vision

Harnessing a revolution in biology for human health®.

Our Mission

Build a top-tier, global, independent biopharmaceutical company founded on RNAi.

Our Core Values

Commitment to People, Innovation & Discovery, Sense of Urgency, Open Culture, and Passion for Excellence.

The Alnylam Story—
From Possibilities to PatientsTM

From Possibility to Patients: The Eureka Moment

The Eureka Moment

In truly groundbreaking research, there is often a moment of clarity, a moment when it becomes clear that a discovery has the potential to transform science and medicine as we know it. This is the eureka moment upon which Alnylam was built.

From Possibility to Patients: The Scientific Odyssey—The RNAi Boom


There was a time when interest in RNAi boomed. Everyone wanted a piece of it. Excitement for this promising new approach for treating disease drew in multiple pharmaceutical players, millions of dollars, and ambition to be the first to unlock the power of this new discovery.

From Possibility to Patients: The Scientific Odyssey—The Dark Ages

The Dark Ages

Alnylam faced many challenges in its early history. The dissolution of major partnerships led to turmoil and a loss of faith in the technology outside the walls of Alnylam. Within the company, there remained unwavering belief, continued focus, enthusiasm, and drive to make RNAi therapeutics a reality.

From Possibility to Patients: The Scientific Odyssey—The Slope of Enlightenment

The Slope of Enlightenment

After overcoming seemingly insurmountable challenges, Alnylam has built a robust Research & Development engine and a deep pipeline of investigational RNAi therapeutics with the potential to address a broad spectrum of diseases. Today, Alnylam is dedicated to proving that innovative science, perseverance, and passion can come together to improve the lives of patients.


Receive news and updates on the work at Alnylam that affects you most.